Global Growth Companies With Insider Ownership Up To 29%

As global markets continue to show resilience, highlighted by record highs in major U.S. indices and a mixed performance across Europe and Asia, investors are keenly observing economic indicators such as job growth and inflation trends. In this environment of cautious optimism, stocks with high insider ownership can be particularly appealing as they often signal confidence from those closest to the company's operations.

Top 10 Growth Companies With High Insider Ownership Globally

Name	Insider Ownership	Earnings Growth
Techwing (KOSDAQ:A089030)	18.8%	68%
Shanghai Huace Navigation Technology (SZSE:300627)	24.3%	23.5%
Samyang Foods (KOSE:A003230)	11.7%	24.8%
Pharma Mar (BME:PHM)	11.8%	44.9%
Marinomed Biotech (WBAG:MARI)	29.7%	20.2%
Laopu Gold (SEHK:6181)	35.5%	41.2%
KebNi (OM:KEBNI B)	38.3%	94.5%
Fulin Precision (SZSE:300432)	13.6%	43.7%
Elliptic Laboratories (OB:ELABS)	24.4%	79%
Bergen Carbon Solutions (OB:BCS)	12%	63.2%

Click here to see the full list of 827 stocks from our Fast Growing Global Companies With High Insider Ownership screener.

We'll examine a selection from our screener results.

Truecaller (OM:TRUE B)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Truecaller AB (publ) develops and publishes mobile caller ID applications for individuals and businesses across India, the Middle East, Africa, and internationally, with a market cap of SEK22.98 billion.

Operations: The company generates revenue from its Communications Software segment, totaling SEK1.95 billion.

Insider Ownership: 16%

Truecaller is poised for significant growth, with earnings forecasted to grow at 26.2% annually, surpassing the Swedish market's average. Despite slower revenue growth at 19.4%, it remains above the market rate of 4.3%. Recent initiatives like Secure Calls enhance its business platform by reducing call spoofing and boosting user trust. Although insider selling has occurred recently, analysts agree on a potential price increase of 27.7%, while share buybacks aim to optimize capital structure and shareholder value.

• Unlock comprehensive insights into our analysis of Truecaller stock in this growth report.
• Our expertly prepared valuation report Truecaller implies its share price may be lower than expected.

Suzhou Zelgen BiopharmaceuticalsLtd (SHSE:688266)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Suzhou Zelgen Biopharmaceuticals Ltd (SHSE:688266) is a company focused on the research, development, and commercialization of innovative biopharmaceutical products, with a market cap of CN¥30.72 billion.

Operations: The company generates its revenue primarily from the pharmaceuticals segment, amounting to CN¥592.35 million.

Insider Ownership: 29.4%

Suzhou Zelgen Biopharmaceuticals Ltd. is experiencing rapid revenue growth, forecasted at 45.4% annually, outpacing the Chinese market's 12.4%. Despite a volatile share price recently, it trades at a significant discount to its fair value. The company reported improved first-quarter results with sales of CNY 167.64 million and reduced net loss compared to last year. Added to the Shanghai Stock Exchange Health Care Sector Index, it is expected to become profitable within three years, exceeding average market growth expectations.

• Click here to discover the nuances of Suzhou Zelgen BiopharmaceuticalsLtd with our detailed analytical future growth report.
• According our valuation report, there's an indication that Suzhou Zelgen BiopharmaceuticalsLtd's share price might be on the expensive side.

Aoshikang Technology (SZSE:002913)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Aoshikang Technology Co., Ltd. specializes in the research, development, production, and sale of printed circuit boards with a market cap of CN¥10.04 billion.

Operations: The company generates revenue primarily from its printed circuit boards segment, amounting to CN¥4.75 billion.

Insider Ownership: 19.7%

Aoshikang Technology is poised for robust growth, with earnings projected to rise significantly at 30.5% annually, surpassing the Chinese market's average. Despite a recent dip in profit margins from 11.6% to 7.4%, the company trades at a favorable price-to-earnings ratio of 31.2x compared to the market's 40x. Recent initiatives include a CNY 180 million share buyback program and dividend affirmations, reflecting strategic capital allocation amidst an unstable dividend history.

• Click here and access our complete growth analysis report to understand the dynamics of Aoshikang Technology.
• The analysis detailed in our Aoshikang Technology valuation report hints at an deflated share price compared to its estimated value.

Next Steps

• Investigate our full lineup of 827 Fast Growing Global Companies With High Insider Ownership right here.
• Looking For Alternative Opportunities? AI is about to change healthcare. These 25 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com